(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage - 24 Dazzling And Well known Island Objections In US
- 3Turkey’s intel chief lays out country’s vision for Middle East, world
- 4Web designers for Independent ventures
- 5RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- Air travelers face higher ticket prices as Iran war drives up oil prices
- Our favorite Space.com stories of 2025
- How to get rid of your Christmas tree — and the 1 thing to never, ever do with it
- Why boosting production of Venezuela's 'very dense, very sloppy' oil could harm the environment
- Before trips to Mars, we need better protection from cosmic rays
- Israeli lawmakers pass bill reviving death penalty for terrorists
- 12 Once-In-A-Lifetime Travel Experiences To Add to Your Bucket List
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- 5 VIP Voice Exhibitions in Energized Movies
